Poland· PL-100110487
Trizivir
A zidovudine, lamivudine and abacavir product containing abacavirum + lamivudinum + zidovudinum, registered in Poland by ViiV Healthcare BV. The same ATC class is registered in 10 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Zidovudine, lamivudine and abacavir is registered in 10 of 19 countries.
Countries holding a registration under ATC J05AR04 (zidovudine, lamivudine and abacavir), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 6 of them publish a price we can compare per daily dose
Zidovudine, lamivudine and abacavir · ATC J05AR04
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Abacavirum + Lamivudinum + Zidovudinum
- Manufacturer
- ViiV Healthcare BV
- Country
- Poland (PL)
- ATC code
- J05AR04
- ATC class
- Zidovudine, lamivudine and abacavir
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 3
- gtin05909990961818
- gtin05909990961832
- gtin05909990961825
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
3 interactions on record for zidovudine, lamivudine and abacavir.
Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Zidovudine, lamivudine and abacavir · interactions on record
3 records
3 more interactions with mechanism and management, from a commercially licensed source.
Sign in to checkSame medicine, other countries
Zidovudine, lamivudine and abacavir in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaTRIZIVIRViiV Healthcare BV, Amersfoort
- SpainTRIZIVIR 300 MG/150 MG/300 MG COMPRIMIDOS RECUBIERTOS CON PELICULAViiv Healthcare B.V.
- FranceABACAVIR/LAMIVUDINE/ZIDOVUDINE VIATRIS 300 mg/150 mg/300 mg, comprimé pelliculéVIATRIS SANTE
- IrelandTrizivir 300 mg/150 mg/300 mg film-coated tabletsViiV Healthcare BV
- NetherlandsAbacavir/Lamivudine/Zidovudine Mylan 300 mg/150 mg/300 mg filmomhulde tablettenMylan Pharmaceuticals Limited
- FinlandTRIZIVIRViiV Healthcare BV
- IcelandTrizivirViiV Healthcare BV
- United StatesABACAVIR, LAMIVUDINE AND ZIDOVUDINELupin Pharmaceuticals, Inc.
Authorised across Europe · EMA
The same active substance is authorised in 6 EEA countries. Names it is sold under:
- France · Abacavir/Lamivudine/Zidovudine Viatris
- Iceland · Trizivir
- Italy · Abacavir/Lamivudina/Zidovudina Mylan
- Liechtenstein · Trizivir
- Netherlands · Abacavir/Lamivudine/Zidovudine Mylan
- Norway · Trizivir
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/45114f39-2c2d-4b63-bb7b-a44dea019207 GET /v1/drugs/45114f39-2c2d-4b63-bb7b-a44dea019207?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "300 mg + 150 mg + 300 mg",
"packaging": "05909990961818 ¦ Rp ¦ Skasowane ¦ EU/1/00/156/001 ¦ 19731\n40 tabl.\n05909990961832 ¦ Rpz ¦ EU/1/00/156/003 ¦ 19732\n1 butelka 60 tabl.\n05909990961825 ¦ Rpz ¦ EU/1/00/156/002 ¦ 57363\n60 tabl. w blistrze\nRpz ¦ EU/1/00/156/004 ¦ 143233\n60 tabl. w blistrze",
"substance": "Abacaviri sulfas 351 mg + Lamivudinum 150 mg + Zidovudinum 300 mg",
"common_name": "Abacavirum + Lamivudinum + Zidovudinum",
"pl_product_id": "100110487",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about zidovudine, lamivudine and abacavir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.